Massachusetts Financial Services Co. MA Has $15.68 Million Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Massachusetts Financial Services Co. MA raised its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 2.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 519,701 shares of the company’s stock after purchasing an additional 13,547 shares during the quarter. Massachusetts Financial Services Co. MA owned 0.92% of Harmony Biosciences worth $15,679,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of HRMY. LSV Asset Management raised its position in Harmony Biosciences by 346.5% in the 1st quarter. LSV Asset Management now owns 335,146 shares of the company’s stock valued at $11,254,000 after buying an additional 260,093 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Harmony Biosciences by 53.7% in the second quarter. American Century Companies Inc. now owns 681,536 shares of the company’s stock valued at $20,562,000 after purchasing an additional 238,140 shares during the last quarter. Capital Management Corp VA bought a new stake in shares of Harmony Biosciences in the first quarter worth $7,018,000. Janus Henderson Group PLC boosted its holdings in Harmony Biosciences by 1,011.7% during the first quarter. Janus Henderson Group PLC now owns 185,083 shares of the company’s stock worth $6,214,000 after purchasing an additional 168,434 shares during the last quarter. Finally, Hedeker Wealth LLC bought a new position in Harmony Biosciences in the first quarter valued at $2,627,000. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences Stock Performance

Shares of NASDAQ HRMY opened at $39.29 on Friday. Harmony Biosciences Holdings, Inc. has a 12 month low of $18.61 and a 12 month high of $39.73. The stock has a 50 day moving average of $35.22 and a 200-day moving average of $32.25. The company has a current ratio of 3.13, a quick ratio of 3.09 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $2.23 billion, a P/E ratio of 17.01, a P/E/G ratio of 0.75 and a beta of 0.73.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.24. The firm had revenue of $172.80 million for the quarter, compared to the consensus estimate of $172.53 million. Harmony Biosciences had a net margin of 17.53% and a return on equity of 22.97%. The company’s quarterly revenue was up 28.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.56 earnings per share. As a group, equities research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.19 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on HRMY shares. UBS Group started coverage on shares of Harmony Biosciences in a research report on Tuesday, September 10th. They set a “buy” rating and a $56.00 price target on the stock. Citigroup started coverage on Harmony Biosciences in a research report on Friday, June 21st. They set a “buy” rating and a $48.00 price target for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $52.00 price target on shares of Harmony Biosciences in a research note on Thursday, September 12th. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Harmony Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $41.33.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.